Immutep (ASX:IMM) has dosed the first patient in its TACTI-004 phase 3 trial evaluating a potential combination therapy for non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.
The trial is assessing Immutep's eftilagimod alfa, a first-in-class MHC Class II agonist, in combination with NYSE-listed Merck's Keytruda anti-PD-1 therapy and chemotherapy as first-line treatment for patients with advanced or metastatic non-small cell lung cancer, per the filing.
The study's dual primary endpoints are progression-free survival and overall survival. Results will support a potential marketing approval application.
The global trial will enroll 756 patients at more than 150 clinical sites in over 25 countries, the filing stated.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.